Six biotechs merge to take on Bridge­Bio, Abeona in 'but­ter­fly skin' dis­ease, with eyes al­so set on Duchenne

A rel­a­tive­ly un­known clin­i­cal-stage biotech, with a med­ical chief who’s been in­volved in mul­ti­ple Bridge­Bio ven­tures, has raised a small fi­nanc­ing round and ap­pears to al­ready have a pric­ing range in mind for a rare dis­ease as­set near­ing a Phase II start.

The com­pa­ny formed in 2020 and has raised close to $20 mil­lion, ac­cord­ing to two SEC fil­ings from this week and last Au­gust.

Phoeni­cis Ther­a­peu­tics is an amal­ga­ma­tion of at least five biotechs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER